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Abstract:
Here we report the NMR solution structures of Mycobacterium
tuberculosis (M. tuberculosis) thioredoxin C in both oxidized and reduced
states, with discussion of structural changes that occur in going between
redox states. The NMR solution structure of the oxidized TrxC corresponds
closely to that of the crystal structure, except in the C-terminal region. It
appears that crystal packing effects have caused an artifactual shift in the α4
helix in the previously reported crystal structure, compared to the solution
structure. Based on these TrxC structures, chemical shift mapping, a
previously reported crystal structure of the M. tuberculosis thioredoxin
reductase (not bound to a Trx) and structures for intermediates in the E. coli
thioredoxin catalytic cycle, we have modeled the complete M. tuberculosis
thioredoxin system for the various steps in the catalytic cycle. These
structures and models reveal pockets at the TrxR/TrxC interface in various
steps in the catalytic cycle, which can be targeted in the design of
uncompetitive inhibitors as potential anti-mycobacterial agents, or as
chemical genetic probes of function.
Keywords: Thioredoxin, Thioredoxin reductase, Mycobacterium tuberculosis,

NMR, solution structure.

Introduction
Mycobacterium tuberculosis (M. tuberculosis) is the causative
agent of tuberculosis, which has a mortality rate of 1.3 million people
in 2008.1 It is estimated that a third of the world population is infected
with a latent form of M. tuberculosis.2 The M. tuberculosis pathogen
resides in the alveolar phagocytes of the host and can resist the
oxidative killing of these immune cells, but the exact mechanism of
this resistance is remains unclear.3 Disrupting this defense could be an
effective means by which that pathogen could be killed, so the proteins
involved in this defense are being pursued as potential targets for new
anti-mycobacterial drugs. The method by which host phagocytes
attempt to kill the invading M. tuberculosis pathogen is via production
of reactive oxygen and nitrogen species, including superoxides and
hydrogen peroxide, which can be toxic to the microbe.4 One method
that M. tuberculosis uses to resist this oxidative attack is via the same
process that eukaryotic cells use to combat oxidative stress, using the
thiol reductants of the thioredoxin system (in addition to other
enzymatic anti-oxidant systems). In other prokaryotic organisms, the
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thioredoxin system keeps cellular proteins in a reduced state, along
with glutathione (mycothiol is used in M. tuberculosis).5–7
Thioredoxins are well-studied proteins, found in all organisms.8
They share common features such as a conserved catalytic motif of
WCXXC, and have a low molecular weight of about 12 kDa.9
Thioredoxins catalyze thiol-disulfide exchange reactions using redox
active cysteine thiols to reduce oxidized disulfide cysteines of proteins,
including metabolically essential enzymes.10–12 The oxidized
thioredoxins are then reduced by thioredoxin reductase (TrxR) in an
NADPH-dependent reaction, via redox active cysteine or
selenocysteine thiols, depending on the host organism.13–15 In plants,
fungi and bacteria, the disulfide reductions in TrxR (~35 kDa) occur
via a sequence of reactions that begins with hydride transfer from
NADPH to a bound FAD cofactor, followed by electron transfer from
FADH2 to the redox-active cysteines, to the thioredoxin, which forms a
mixed disulfide with TrxR before the thioredoxin cysteines are fully
oxidized. In higher organisms, such as mammals, the TrxR (~55 kDa)
transfers the hydride from the NADPH to FAD, then from FADH2 to an
amino-terminal TrxR active site, then to a carboxy-terminal active site
of the TrxR/Trx dimer pair. This TrxR/Trx dimer contains a cysteineselenocysteine redox-active pair, which then transfers electrons to the
thioredoxin in a disulfide exchange reaction.14 Thus, the microbial and
human thioredoxin mechanisms diverge significantly in the steps
involving Trx binding and reduction. Disruption of this process, by
selectively targeting the microbe over the host, could be used to kill
the M. tuberculosis pathogen. Selective targeting should be possible
since the Trx binding site is in a different region of the TrxR.
Furthermore, the M. tuberculosis thioredoxins are only 35% identical
to the human Trx, and the M. tuberculosis TrxR is only 28% identical
to human TrxR. While these proteins are functionally related from
microbe to man, the TrxR’s are structurally and mechanistically quite
different.16,17
The catalytic cycle of the thioredoxin system from various
prokaryotic sources has been extensively studied, with the best
characterized being that from E. coli. The first E. coli Trx solution
structures were reported over 20 years ago.18–22 Building on this rich
literature, a comprehensive study from the Ludwig lab23 determined
structures for the various steps in the E. coli thioredoxin system
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catalytic cycle, providing a structural complement to the mechanistic
knowledgebase surrounding the microbial thioredoxin system. While
the thioredoxin system from E. coli is well characterized, that of M.
tuberculosis is not.3 Because the E. coli thioredoxin system is so
similar to that of M. tuberculosis. (TrxR 45% identity, 63% homology,
and Trx 50% identity and 64% homology), the structural studies
presented herein build on what has been learned about the E. coli
system, to provide a foundation for future structure-based design of
inhibitors that disrupt the M. tuberculosis thioredoxin system, either as
chemical probes of function, or as potential anti-mycobacterial agents.
Analysis of structures and models for various steps in the M.
tuberculosis thioredoxin catalytic cycle, as opposed to individual static
snapshots of single proteins (ex. TrxR), may suggest novel strategies
for inhibition.
The thioredoxin system in M. tuberculosis is comprised of three
thioredoxins (TrxA, TrxB, and TrxC) and one thioredoxin reductase
(TrxR).3, 24, 25 It has been shown that M. tuberculosis TrxB and TrxC
behave as general disulfide reductases with near equal reduction
potential (−262 mV vs. −269 mV), while TrxA is observed to have only
a weak capacity to act as a disulfide reductase, and was found to not
be a substrate for TrxR under the assay conditions tested.3 It has also
been shown that the ability of M. tuberculosis to survive redox stress,
while dependent on TrxR, is not dependent on the expression of just
one thioredoxin. This suggests that having multiple thioredoxins in M.
tuberculosis may provide a “redundant system” to ensure survival
under oxidative conditions.3 The thioredoxin system of M. tuberculosis
is increasingly viewed as a viable drug target for novel antimycobacterials, as long as a drug can be designed that knocks out the
entire M. tuberculosis thioredoxin system (ex. inhibit TrxR catalytic
turnover with all Trx’s).26 Of particular interest would be inhibitors that
remain effective at high levels of competing substrate, either Trx or
NADPH; this would be uncompetitive inhibition. Cells cannot achieve
resistance to such uncompetitive inhibitors by increasing levels of
substrates; but, design of such inhibitors requires structural
information that enables more than just simple targeting the NADPH or
Trx pockets on TrxR, as has been the focus to date.17 Design of
uncompetitive inhibitors requires a knowledge of potential pockets that
exist during the catalytic cycle and that could be occupied by inhibitors
(in the presence of Trx substrate), and that stabilize reaction
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intermediates, thereby stopping catalytic turnover in a manner that
cannot be overcome at high substrate. Studies presented herein will
provide structures and models for various steps in the catalytic cycle of
the M. tuberculosis thioredoxin system to facilitate design of such
inhibitors.
Structural studies presented herein focus initially on M.
tuberculosis TrxC (Fig. 1), and modeling of its interactions with TrxR
throughout the catalytic cycle, based on NMR chemical shift
perturbation studies (Fig. 2). While the crystal structure of TrxC in the
oxidized state has been solved, there is no structure of TrxC in the
reduced state, and no structural studies of interactions between TrxR
and TrxC.25 Furthermore, it was previously suggested (but never
proven) that the crystal structure of TrxC may have had distortions
due to crystal packing forces that affect the C-terminal helix.25 Studies
presented herein establish that this is in fact the case. Previous studies
of the different redox states of prokaryotic thioredoxins have shown
that there are subtle changes in structure in going from the oxidized to
the reduced state.22, 27, 28 Most of the changes occur in the active site
near the redox active cysteines, with some conformational flexibility
observed in the active site loop.25, 29 Whether this is also true in M.
tuberculosis TrxC is not known, since there is no structure of reduced
TrxC. Studies presented herein will provide an analysis of differences
between reduced and oxidized TrxC. Beyond this, studies will address
how these forms of TrxC may interact with TrxR at different steps in
the catalytic cycle (building on the E. coli work from the Ludwig lab),
and whether these intermediates suggest unique opportunities for the
design of uncompetitive inhibitors.
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Figure 1

Solution NMR structures of TrxC: (a) the ensemble for oxidized TrxC with

a backbone RMSD of 0.54 Å, (b) the ensemble for the reduced state of TrxC with a
backbone RMSD of 0.50 Å, and (c) overlay of the median structures for both redox
states, colored as in panels (a) and (b). Note: disordered N- and C-terminal residues
1–6 and 113–116 have been omitted for clarity in panels (a) and (b). (d) Overlay of
the median NMR solution structure for the oxidized TrxC (red) and the crystal
structure of oxidized TrxC (gray), with the active site disulfides shown in yellow. The
only significant deviation is in the C-terminal helix, α4, which in the crystal structure
participated in an interaction with another TrxC in the asymmetric unit.
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Figure 2

2D 1H-15N HSQC spectra of (a) the oxidized state of TrxC (red) with all

the backbone N-H chemical shifts assigned, and (b) the oxidized (red) and reduced
(black) states of TrxC, with the large chemical shift changes associated with disulfide
reduction labeled.
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Materials and Methods
Protein Expression and Purification
The plasmids containing the Rv3914 gene (TrxC) in the pET22b
vector and the Rv3913 gene (TrxR) in the pET23a vector were
obtained from Tuberculosis Vaccine Testing and Research Materials at
Colorado State University and from Dr. Mande from the Center for DNA
Fingerprinting and Diagnostics in Hyderabad, India. Both expression
constructs produced protein with a C-terminal poly-histidine tag
(Supplementary Figure S4); plasmids were transformed into E. coli
BL21-(DE3) Rosetta cells from Novagen and grown overnight at 37° C,
then inoculated into 2 L of LB (Luria Bertani) media supplemented with
a vitamin mix that included riboflavin (needed for TrxR flavin
production). Cells containing the TrxR gene were grown until O.D. 600
nm reached 0.7, at which point cells were induced for 4 hours with 1
mM IPTG. For expression of TrxC protein cells were grown to 0.7 at
O.D. 600 at which point the cells were spun down at 7000 rpm and
washed with M9 minimal media salts (pH 7.0). Cell pellets were
transferred to 0.5 L of M9 minimal media containing 0.5 grams 15NH4Cl
and 2.0 grams of 13C-glucose as the only sources of nitrogen and
carbon, to yield uniformly labeled protein.30 The cells were allowed to
acclimate for 1 hour and then induced with 1 mM IPTG for an
additional 4 hours at 37° C, then harvested. The bacterial pellet was
resuspended in lysis buffer consisting of 50 mM Tris base, 300 mM
NaCl, 5 mM imidazole, and 10% glycerol at pH of 7.8, and lysed using
sonication. The lysate was clarified by centrifugation at 15,000 RPM for
30 minutes and the supernatant loaded onto 1 mL of nickel-Sepharose
(Amersham Sciences) resin at 1 mL/minute. The bound protein (TrxC
or TrxR) was then washed with lysate buffer, then with lysate buffer
containing 25 mM imidazole, and then eluted using lysate buffer
containing 300 mM imidazole. The eluted protein was than dialyzed
with 40 mM potassium phosphate buffer at pH of 6.3 (for NMR
structure studies) and pH of 7.0 (for TrxC/TrxR binding experiments)
and concentrated to 1 mM using Amicon Ultra-4 centrifugal device
(Millipore) with protein concentration determined by the absorbance at
280 nm using extinction coefficients of 11,000 and 14,440 L/mol-cm
for TrxC and TrxR respectively, based on ProtParam calculations
(http://expasy.org/tools/protparam.html). While estimation of protein
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concentration in this manner may slightly overestimate TrxR
concentration (the FAD has some absorbance at 280 nm), exact
stoichiometry is not required for titration of TrxC with TrxR, because
we see complete disappearance of crosspeaks at < 1:1 stoichiometry
due to exchange broadening. The purpose of the TrxR/TrxC titration is
simply to identify interface crosspeaks, and the residues corresponding
to those crosspeaks. Flavin incorporation into TrxR was verified using
UV-Visible spectroscopy (Supplementary Fig. S5). For studies of
reduced protein, 5 mM DTT was added.

NMR Spectroscopy and Structure Calculation
All NMR experiments were performed on a 600 MHz Varian NMR
System at 599.515 MHz using a triple resonance cryoprobe with z-axis
gradients at 25 °C. Backbone assignments were obtained using 2D 1H15
N HSQC, and 3D HNCO, HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH,
and HNCACB spectra. Side chains were assigned using CC(CO)NH,
HBHA(CO)NH, HCC(CO)NH, and HCCH-TOCSY spectra. Distance
restraints were obtained from 3-D 15N-NOESY, 13C aliphatic NOESY,
and 13C aromatic NOESY experiments, which were obtained using 150
ms mixing times. Structures were calculated using these distance
restraints with the program CYANA,31–33 in conjunction with backbone
phi and psi angle restraints as predicted from TALOS34 based on
chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms. Initial structures
were obtained using the noeassign macro of CYANA,33 followed by
manual refinement using the calibration of peaklists by the CYANA
function caliba, with the disulfide bond added as a restraint for the
oxidized structure. A final ensemble of 500 structures was calculated,
and the 100 conformers with the lowest target function were then
selected for water refinement using AMBER.35 Using implicit solvent, a
500 step energy minimization was first performed on the 100
structures (no restraints) followed by two cycles of 30 ps simulated
annealing from 1000K to 0K, with distance and dihedral restraints
applied. After the MD simulated annealing, a 2000 step minimization
with restraints was applied in implicit solvent and analyzed for distance
and dihedral penalties and rank ordered by lowest AMBER energy. The
20 lowest energy structures were then selected for the final ensemble
(Fig. 1), and were analyzed using the Protein Structure Validation
Software suite.36 NMR spectra were processed using NMRPipe37 and
analyzed using NMRView38 and Sparky.39 Processing was performed
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with a cosine bell window function in the direct and indirect
dimensions.

Structural Modeling of Intermediates in the M.
tuberculosis Thioredoxin Reductase Catalytic Cycle
The M. tuberculosis thioredoxin reductase crystal structure (pdb
code 2A87)17 had previously been solved in the oxidized state (in what
is referred to as the FO conformation). To create a model of TrxR in the
reduced state, where the disulfide is converted to surface free thiols
(available to react with and reduce thioredoxins), the coordinates of
the E. coli homolog of TrxR bound to a thioredoxin (pdb code
1F6M)(40) were used as template. Specifically, the M. tuberculosis
TrxR (oxidized) structure was superimposed on the E. coli TrxR
(reduced) structure. But, since the reduced E. coli TrxR is known to
have a 66° domain rotation relative to the oxidized TrxR,17, 40 this
same rotation was created in the M. tuberculosis structure. To do this,
the pdb file of M. tuberculosis TrxR was split at amino acids 117 and
241 so that the FAD and NADPH domains could be separated. The
separated NADPH and FAD domain coordinates were then
superimposed onto the coordinates of the E. coli NADPH and FAD
domain using Pymol41, then rejoined and then minimized using
AMBER.35 This yielded what is referred to as the FR conformation. To
model the various oxidation states of the TrxR/TrxC complexes,
including the mixed disulfide between TrxR and TrxC, structures were
minimized with a restrained disulfide bond between the cysteines
(oxidized) or left with no restraint (reduced). All AMBER minimizations
were performed with 2000 steps in implicit solvent.

Thioredoxin System NMR Binding Experiments
In order to establish which redox states of TrxC, TrxR and
NADPH/NADP+ interact, and where interacts occur, chemical shift
perturbations were monitored using 15N-labeled TrxC (reduced or
oxidized) (Fig. 2). If binding occurs, based upon observation of
chemical shift changes in HSQC spectra, chemical shifts are mapped
onto the surface of TrxC to guide and confirm modeling of the
TrxC/TrxR complexes, described in the previous section. These data
were used, in part, to construct the models in Fig. 3, as described in
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Fig. 4 and Supplementary Fig. S2. TrxC and TrxR solutions were
exchanged into 50 mM potassium phosphate buffer at pH 7.0, then
concentrated to 1 mM each. TrxC was diluted to 320 μM in the absence
of DTT, so that it was in the oxidized state. TrxR was then added to
the TrxC NMR sample, so that both proteins were at equal
concentrations of 250 μM. NADPH was then added to the sample at 1
mM so that TrxR would reduce the disulfide of TrxC. As a control to
test for binding in the presence of the different redox states of the
cofactor, NADP+ was added to the sample at 1 mM. 1H-15N HSQC
experiments were acquired after every addition, and pH was measured
to ensure that it remained at 7.0. As a control for the reduced state,
1
H-15N HSQC spectra were acquired for TrxC in the oxidized state, and
then reduced by DTT at pH 7.0.
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Figure 3

The complete redox and catalytic cycle for the M. tuberculosis thioredoxin

system, modeled after the E. coli thioredoxin catalytic cycle. The cycle begins with free
TrxR (colored red) in the oxidized state, with bound NADP+, with the first step being
release of NADP+ and a simple domain rotation to produce the FO conformation. FR and
FO refer to the reduced or oxidized conformations (not the redox state) of TrxR, which
are related by a 66° rotation of the NADPH and flavin domains. TrxC (ox and red)
structures are those reported herein (colored blue), TrxR (FO) is the previously
reported crystal structure, while models for the various complexes were constructed
based on structural and functional data for the E. coli thioredoxin system, and
chemical shift perturbation studies. Expansions show the redox state of relevant thiols
or disulfides. Each modeled complex was minimized with AMBER. This cycle can also
be visualized via a molecular animation (Supplementary materials), and structure
models are available to be used in docking or structure-based drug design efforts.
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Figure 4

Definition of the TrxR/TrxC interface using chemical shift perturbation

studies. (a) Several HSQC spectra were overlaid, with blue crosspeaks corresponding
to free reduced TrxC (in presence of 1 mM DTT). Green crosspeaks correspond to a
~1:1 complex between TrxC/TrxR at 250 μM (TrxC in slight excess over TrxR), with a
fourfold excess of NADPH added. In cases where there was exchange broadening due
to TrxR binding to TrxC, green peaks are no longer visible; so, the presence of blue
identifies residues that are likely to be at the TrxC/TrxR interface. Orange crosspeaks
correspond also to the complex between TrxC/TrxR at 250 μM, but now with a fourfold excess of NADP+ added in addition to 1 mM DTT. The exact match between green
and orange crosspeaks suggests these two ternary complexes are similar, if not
identical, and would correspond somewhat to intermediate F (but possibly with the
mixed disulfide reduced) in Fig. 3. All spectra were acquired at pH 7.0. (b) Interface
residues, which are largely hydrophobic, are shown as a surface rendering (white).
This is the interface that forms when TrxR binds to and reduces an oxidized TrxC, and
includes F142 and F143 on TrxR. (c) Residues on TrxC that show chemical shift
perturbations or line broadening (from panel (a)) upon binding to TrxR have been
mapped on the TrxC solution structure as blue Van der Waals spheres. These residues
define the binding interface with TrxR (in panel (b)).

Thioredoxin System Interface Inhibition Docking and
Titration Experiments
An in-house collection of 10,000 drug-like chemicals was docked
into open spaces at the interface of the TrxC-TrxR complex using
Autodock 4.2.42, 43 The grid box was centered at the interface and was
24.75 Å × 25.5 Å × 29.25 Å. Autodock 4.2 docked each ligand 50
times, scored the pose based on the program’s force field, and
clustered each pose based on a root-mean-squared difference from the
other poses. NMR screening of individual chemicals was prioritized by
the cluster’s mean binding energy and population. Compounds that
scored favorably were then dissolved in DMSO to a concnetration of 5
mM. Binding studies were performed by combining 200 μM TrxC, 250
μM TrxR, and 0.80 mM NADPH in the NMR buffer described above.
Compounds were added at 200 μM (DMSO ~4% by volume) and HSQC
spectra acquired before and after compound addition, and analyzed for
any chemical shift perturbations.
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Results and Discussion
NMR Solution Structures of Oxidized and Reduced
Thioredoxin C
The solution structures of M. tuberculosis thioredoxin C were
solved by NMR (Fig. 1), with 2036 NOE derived restraints and 168
angle restraints in the oxidized state and 2114 NOE restraints in the
reduced state with 169 angle restraints. Statistics describing the
restraints used in calculation, precision, and quality of the structures
are summarized in Table I. The ensemble of structures for oxidized
TrxC (PDB entry 2L59 and BMRB entry 17268) has a backbone RMSD
of 0.54 Å, and 0.50 Å for the reduced state (PDB entry 2L4Q and
BMRB entry 17242), shown in Figs. 1A and 1B. To ensure that the
cysteines were reduced, 5 mM DTT was added to the protein sample
and chemical shifts were monitored before and after each experiment,
using a 1H-15N HSQC (Fig. 2A–B) spectrum. Reduction of the active site
cysteines results in a decrease in the 13Cβ chemical shifts from 44.6 to
26.9 ppm and 35.1 to 27.6 ppm for Cys37 and Cys40 respectively,
consistent with the additional shielding that is present with the
electron rich thiol, compare to the disulfide. After addition of DTT to
oxidized TrxC, those residues that are affected the most are located
along the active site loop, including F32, A34, T35, C37, G38, and
C40.
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Table I

NMR and water refinement statistics and analysis for solution structures of

both redox states of Mycobacterium tuberculosis

Analogous to the situation with the E. coli thioredoxin solution
structures,18–22 the oxidized and reduced forms of TrxC are very similar
to each other, showing only small differences between oxidized and
reduced states, with a pairwise RMSD of only 0.53 Å between the
ensembles (Fig. 1C). Consistent with other thioredoxins, TrxC in both
states has the characteristic folding pattern of 4 α-helices surrounding
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a 5 stranded beta sheet core, consisting of three parallel strands and
two antiparallel strands. The redox active cysteine residues C37 and
C40 are located in the conserved active site loop (C37-G-P-C40) that
leads into the α2 helix, which in both redox states is a bent helix. The
active site of TrxC includes a predominately hydrophobic core including
two Ala (34 and 44), two Pro (39 and 81), an Ile (80), and a Val (43)
residue. Both Trp (33 and 36) indole rings are within 6 Å of the two
Cys’s, with W36 also forming the interface surface that interacts with
TrxR (Fig. 4). The disulfide in the oxidized state has the typical 90° χss
angle for the C-S-S-C linkage. Interestingly, roughly the same
geometry with the same χss angle is present in the reduced state. The
most dramatic change in going from oxidized to reduced state is the
distance between the Cys residue sidechains, with the S-S distance in
the oxidized state of the median structure in the ensemble having a
distance of 2.0 Å, compared with 3.5 Å in the reduced state (Fig. 1C).
That is, overall geometry is roughly the same before and after S-S
bond formation; but, the thiols move 1.5 Å closer together as the bond
forms.
The N-terminal (α1) helix is somewhat irregular, but is nearly
identical between the two redox states, and is the same as in the
crystal structure of M. tuberculosis TrxCox25 as well as both E. coli Trx
solution structures. The α4 helix spans residues 101–111, but begins
to show fraying at L108. There are some differences between the two
redox states in the turn region linking the α1 helix to the β3 sheet
(residues 22–26), and the α3 helix connecting to the β4 sheet
(residues75–81). The latter region closely contacts the active site
region. These regions are probably dynamic in nature, and show
similar effects in the E. coli solution structures of the different redox
states (Fig. S1).

Comparison to the M. tuberculosis TrxC Crystal
Structure
The M. tuberculosis TrxC crystal structure (pdb code 2i1u)25 was
solved in the oxidized state, and is nearly identical in secondary
structure to our solution structure, with a pairwise RMSD of 0.83 Å
between the crystal structure and the median structure from the
ensemble (Fig. 1D). But, there is one significant difference – and that
is with regard to the orientation of the C-terminal α4 helix. It was
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noted in the crystal structure study that the protein crystals packed
such that the C-terminus (residues 110–114) in the α4 helix rested in
the active site groove of an adjacent protein in the crystal lattice,
which the authors noted could cause a structural perturbation. Based
on our solution structure of oxidized TrxC, this crystal packing effect
does in fact seem to have caused the α4 helix to be pushed up 2.7 Å
towards the β5 strand, and rotated in towards the β4 strand (Fig. 1D).
Residues 108–115 in the crystal structure are disordered, perhaps so
that those residues can occupy the active site of a neighboring TrxC
protein. However, residues 108–111 still retain helical shape (as
mentioned above) before becoming disordered at residues 112–115 in
our solution structure. Although it is possible that some difference in
the α4 helix may stem from the C-terminal histidine tag, we believe
this is unlikely since the solution structure maintains the characteristic
thioredoxin folding pattern, and is more compact than the crystal
structure (Figure S1). Even though the distortion of the α4 helix and
its ability to participate in a protein-protein interaction may be an
artifact of crystal packing, its ability to participate in this interaction
may also hint of a biologically relevant role. That is, since α4 is
flexible, it is possible that it plays a role in protein-protein interactions
with TrxR, which may require motion of this helix. In this regard, we
have also performed calculations of generalized order parameter of
TrxC, based on the “Random Coil Index”44, and found that several
active site loop regions are predicted to have low order parameters (S2
< 0.8), including the loop that leads into the α4 helix (Supplementary
Fig. S3). Flexibility in these loops may indicate they can function as
hinges that enable motion of the N- and C-terminal helices α1 and α4,
to optimally fit into the binding site presented by TrxR.

Structures and Models of M. tuberculosis Thioredoxin C
(oxidized and reduced) and Thioredoxin Reductase
throughout the Thioredoxin Catalytic Cycle
After having reduced other proteins in the cell, the oxidized TrxC
must be regenerated to the reduced state by the enzyme thioredoxin
reductase (TrxR). This process had been thoroughly studied in E. coli,
culminating in a structural characterization of the various steps in the
TrxR catalytic cycle.40 Fig. 3 presents the corresponding structures and
structural models for the M. tuberculosis TrxR/TrxC system in different
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redox states, depicting the complete redox cycle between TrxR and
TrxC, using the M. tuberculosis TrxR crystal structure17, our TrxC
structures (oxidized and reduced), and the various E. coli structures40
as templates, with protein complexes created or confirmed based on
chemical shift (and line-width) perturbation studies. Chemical shift
mapping studies used to create these complexes are summarized in
Fig. 4 and Supplementary Fig. S2. M. tuberculosis. TrxR is known to
undergo a large domain rearrangement, to position the reactive
cysteines so that they are able to react with the disulfide on the
thioredoxin substrate. The crystal structure of the M. tuberculosis TrxR
is in the oxidized conformation (FO), with its disulfide buried in the
protein interior, near the isoalloxazine ring of FADH2; FADH2 provides
the electrons to reduce this disulfide (step B to C in Fig. 3). The
reduced state of M. tuberculosis TrxR (FR), with its cysteines now at
the surface, and the NADPH close to the FAD (D in Fig. 3), was
modeled using the E. coli thioredoxin reductase structure as a
template (pdb code 1f6m).40 This structure was used to guide initial
positioning of the M. tuberculosis TrxR FAD and NADPH domains. In
this manner, structural models have been created for all the steps in
the thioredoxin reaction sequence (Fig. 3), using chemical shift
perturbation data to define the TrxR and TrxC interface (see below).

NMR Data Defining the Binding Interface between M.
tuberculosis TrxC and TrxR
It has previously been proposed that the E. coli TrxR exists in a
dynamic equilibrium between two conformations (FO and FR),23
irrespective of the state of oxidation for the flavin or cysteines. It is
hypothesized that changing redox state or binding to the thioredoxin
(Trx) substrate merely shifts the FO/FR equilibrium. To determine what
oxidation state the proteins (TrxC and TrxR) must be in for binding to
occur, a series of 1H-15N HSQC titration experiments were performed
so that changes to the state of the proteins in different oxidative
states could be monitored (Fig. 4; Supplementary Fig. S2). Chemical
shift changes could be due to binding or to conformational/structural
changes induced by redox changes; the latter effects are known from
DTT titrations of isolated TrxC (Fig. 1B). When oxidized TrxR, in the
absence of NADPH, was added to TrxC, there were no chemical shift
changes to TrxC (Fig. S2), indicating that oxidized TrxR (that has no
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NADP(H) cofactor bound) cannot bind to TrxC. Interestingly, a small
amount of TrxC that was present in a reduced state was converted to
a fully oxidized state, indicating that even though the oxidized TrxC
cannot bind, the reduced TrxC can bind to oxidized TrxR (lacking
NADP(H)) and react in what would be the reverse of the biologically
relevant direction (high NADPH concentrations ensure the reductive
reaction is favored in vivo). When the reducing agent (NADPH) for the
thioredoxin system was added in excess (4-fold), all of the oxidized
TrxC was converted to the reduced state in the presence of TrxR, via
the TrxR-catalyzed reduction (Supplementary Fig. S2); this is
consistent with the reduced TrxR/NADPH being able to bind TrxC.
While there were no chemical shift differences in comparing the
TrxR/NADPH-reduced TrxC (TrxR present) with the DTT-reduced TrxC
(TrxR absent), the presence of TrxR did cause disappearance of some
TrxC crosspeaks due to exchange broadening (see below). This
exchange broadening identifies residues at the TrxR/TrxC interface,
thereby facilitating construction of properly docked TrxR/TrxC models
(Fig. 3).
When the spectra for the TrxC/TrxR mixture, which has been
reduced using NADPH or DTT (+ NADP+), were overlaid (Fig. 4), there
were again no distinguishable chemical shift changes. When compared
to the spectrum for unbound TrxC (reduced), there are a number of
residues that disappear due to exchange broadening, due to binding
interactions between TrxC and TrxR. The residues that showed
exchange broadening were mapped onto the reduced state solution
structure of TrxC in Fig. 4. The majority of these residues are in the
active site region of the protein (F32, A34, T35, W36, C37, T67, V78),
and these residues create a hydrophobic surface that interacts with
TrxR, and that was used to define the protein-protein interface region
for constructing the structural models in Fig. 3. Based on these results,
although TrxR may be sampling both FO and FR states, TrxC will only
bind to the reduced (free thiol) form of TrxR with cofactor (NADPH)
bound, not to the FO state that is lacking NADPH cofactor.

Analysis of the M. tuberculosis Thioredoxin Cycle
Models
As illustrated in Fig. 3, and by analogy to the E. coli system, the
catalytic cycle for the M. tuberculosis thioredoxin system is shown
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starting in the conformation described as “FR” (intermediate A in Fig.
3), so that the active site cysteines have just finished reducing TrxC
(which was released in the previous step), and there are bound NADP+
and FADH2 cofactors. It is called the FR state because of the relative
orientation of the NADPH and FAD domains such that the NADPH
binding site is close to the FAD (and the thiol/disulfide is distal).
Assuming M. tuberculosis TrxR behaves as the E. coli reductase, it will
then undergo a 66° rotation around the NADPH binding domain to
bring the disulfide bonded cysteines (C145 and C148) proximal to the
isoalloxazine ring of FADH2, while the NADPH binding pocket moves
away from the FADH2, thereby allowing NADP+ to be released (this
creates intermediate B). This also positions the isoalloxazine ring of
FADH2 to within 3.7 Å of the S atom of Cys148 (now TrxR is in the “FO”
state), which permits electron transfer from flavin to the disulfide
(transfer will most likely be to the more proximal cysteine, Cys148).
After the FADH2 reduces the disulfide, the sulfur inter-atomic distance
increases from 2.0 Å to 3.7 Å, giving a slightly smaller χ angle across
what was the disulfide. After reduction, a general base (likely to be
D149, which is 5.3 Å from the thiol of C148) abstracts a proton from
C148 to produce a thiolate that is ready to attack the disulfide of the
thioredoxin (intermediate C converted to D).45 NADPH then binds to
TrxR, and the NADPH domain undergoes another 66° rotation to bring
the reduced active site cysteines away from the FAD isoalloxazine ring,
and back to the surface (back to the FR conformation) of the protein,
core that defines the TrxC binding pocket (the concave pocket on the
bottom of intermediate D in Fig. 3). Elsewhere in the protein in
intermediate D, the NADPH nicotinamide ring comes to within 3.4 Å of
the isoalloxazine ring of FAD so that it can reduce the N5 position of
FAD, again producing FADH2. The FADH2 can once again reduce the
disulfide of TrxR, later in the catalytic cycle.
The TrxR is now in a conformation that can bind and then
reduce TrxC (intermediate E). Inspection of this TrxC/TrxR structural
model reveals that helix a4 is in contact with the mobile NADP(H)
domain of TrxR (the α4 helix is on the far left side of the blue TrxC, as
shown in Fig. 3, intermediates E–G). This same α4 helix was distorted
in the crystal structure of TrxC, and is attached to the core TrxC
structure via a flexible linker (predicted S2 < 0.8; Supplementary Fig.
S3) based on our solution NMR studies. It appears that this mobile α4
helix permits binding of TrxC to the TrxR FR state (the FO state can’t
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bind Trx, because it has this TrxR interface rotated 66° away). Also of
interest is that the α1 helix, which is likewise attached to the TrxC core
via a flexible linker, makes contact on the opposite side of the TrxR
pocket; and, the distortion (kink) in helixα1 creates a somewhat
convex surface that may be essential for matching the concave shape
of the TrxR pocket (the far right side of the blue TrxC structure in
intermediate E of Fig. 3). Thus, a majority of the TrxR/TrxC binding
interface is comprised of the α1 and α2 helices, which form a convex
recognition surface on TrxC.
In addition to TrxR interactions with the TrxC α1 and α4 helices,
the complex appears to be stabilized by a hydrophobic interface
produced in the FR state by TrxR residues F142 and F143, which
interacts with TrxC residues A34, P39, V43, A44, A72, V78, I80, and
P81. Fig. 4 shows a view of the binding interface between TrxR and
TrxC, identified using chemical shift mapping, with surface rendering
showing the hydrophobic pocket. Of particular interest is that W36 of
TrxC, which is conserved in all thioredoxins. W36 has its indole ring
situated in this hydrophobic pocket, with the ring NH hydrogen
bonding to the carboxyl group of Asp66, at a distance of 1.9 Å. This
interaction is likely to be important for proper positioning of the TrxC
C37, for reaction with the TrxR thiol/disulfide (C145, C148). The
thiolate of C148 in TrxR is 4.9 Å from the disulfide-linked cysteine thiol
(C37) of TrxC (intermediate E). Attack of C37 on C148 (disulfide)
would produce the mixed disulfide between the two proteins
(intermediate F), which is analogous to the mixed disulfide structure of
E. coli TrxR/Trx that was structurally characterized by the Ludwig
group.40 The free thiolate in TrxR (Cys145) then attacks Cys148 of the
mixed disulfide, thereby producing fully reduced TrxC in the thiol
reduced state (intermediate G). The newly reduced TrxC is released
from the now oxidized TrxR, which is in the same state as Fig. 4A,
thereby completing the thioredoxin catalytic cycle. The structural
changes associated with this catalytic cycle can also be viewed as a
molecular animation that was created using PyMol (supplementary
materials). This series of thiol/disulfide exchanges is distinct from, and
occurs in a different active site region, in the mammalian thioredoxin
system. Accordingly, targeting this active site region in drug design
efforts could provide compounds that are specific for microbial over
mammalian enzymes.

Proteins, Vol. 81, No. 4 (April 2013): pg. 675-689. DOI. This article is © Wiley and permission has been granted for this
version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further
copied/distributed or hosted elsewhere without the express permission from Wiley.

21

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Conclusion
Developing an inhibitor that targets the M. tuberculosis.
thioredoxin system rather than the human thioredoxin system would
provide a novel route to anti-mycobacterial drugs. The function of the
thioredoxin system, from microbe to man, is to maintain redox
homeostasis by keeping cellular proteins reduced; and, in doing this,
Trx becomes oxidized, so must be reduced by TrxR. The M.
tuberculosis. TrxR undergoes a domain rotation in to move the NADPH
and FAD(H2) in proximity to each other, and to move the reduced
active site cysteines proximal to bound Trx.17 The human thioredoxin
reductase instead uses a cysteine-selenocysteine active site on a
flexible carboxy-terminal tail that is absent in the microbial enzyme, to
shuttle FAD(H2) electrons to its bound thioredoxin (Figure 5B).14 In
comparing the models from M. tuberculosis., described herein, and the
recently published human thioredoxin system16, it becomes clear that
there are significance structural differences (Fig. 5), along with the
mechanistic differences, that can be exploited for selective inhibition of
the microbial system. The human thioredoxin reductase has an
additional domain that interacts with Trx (Fig. 6, interface domain, Fig.
5B and 5C), that is absent in the microbial system. Furthermore, the
active site cysteines (that receive electrons from FADH2) are not
directly exposed to the bound Trx, as they are in the microbial system.
Of particular importance is the absence of the binding pocket between
the Trx and TrxR that was observed in M. tuberculosis complex
(compare Figs. 3B and and5B),5B), because the human system uses
the C-terminal domain for the final electron transfer step to bound Trx.
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Figure 5

Comparison of the M. tuberculosis. and human Trx-TrxR complex. (a) M.

tuberculosis. Trx (blue)-TrxR (red) mixed disulfide. (b) Human Trx (orange)-TrxR
(teal) mixed disulfide. Note the carboxy-terminus of the dimer pair is highlighted in
violet and forms the mixed disulfide. (c) Overlay of the M. tuberculosis. and human
thioredoxin systems. (d) Close up of M. tuberculosis thioredoxin complex disulfide
from Figure 5(c). (e) Close up of the human thioredoxin complex disulfide from Figure
5(c).

Figure 6

Comparison of the three thioredoxin reductases discussed in this study.

The M. tuberculosis. TrxR shows 45% identity and 63% homology to the E. coli TrxR
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and 14% identity and 22% homology to human TrxR1. ○ denotes active site cysteines.
∅ denotes cysteines that form mixed disulfides between the thioredoxin and
thioredoxin reductase. ⊙ denotes the selenocysteine from human thioredoxin
reductase.

Besides providing insights into mechanism, and providing
structural hypotheses that can be tested with future mechanistic
studies (ex. using site-directed mutagenesis), the models presented
herein (Fig. 3) can be used to facilitate structure-based design of
inhibitors that selectively block the M. tuberculosis thioredoxin
catalytic cycle, by targeting the Trx/TrxR interface. While inhibitors
could be designed to block either the NADP(H) or TrxC substrate
pockets on TrxR, the former class would yield inhibitors that might not
be selective for the microbial system and which would be competitive
versus cofactor. The latter approach is attractive, but suffers from the
usual challenge of finding inhibitors that bind to broad protein-protein
recognition surfaces; and, competitive inhibition can be overcome by
the pathogen increasing expression levels of TrxC. A third approach
might be to design inhibitors that occupy pockets that appear in the
catalytic cycle at the Trx/TrxR interface, and are present even when
Trx substrate is bound, so that binding of an inhibitor might stabilize
that intermediate in the presence of substrate and thereby block
catalytic turnover. This is the general concept behind uncompetitive
inhibition. To illustrate the feasibility of the strategy of targeting
interface pockets, a library of 10,000 compounds was docked into a
pocket that is present in intermediates E, F and G (Fig. 3), at the
interface of TrxR and TrxC. Compounds with reasonable drug-like
appearance and properties (ex. adherence to Lipinski Rule of 5) are
found that fit into this pocket (Fig. 7). Initial characterization of one of
these compounds, by titrating onto the TrxR/TrxC complex, has shown
some cross-peak perturbations, including the NH of interface residue
W33. This result suggests feasibility of identifying compounds that
bind at the TrxR/TrxC interface. More in-depth studies are needed to
fully characterize the potential druggability of this binding site, by
identifying and characterizing multiple inhibitors and establishing
structure-activity relationships for binding at the TrxR/TrxC interface.
These studies should include verification of binding by multiple
techniques (direct binding and enzyme activity measurements), as well
as MIC measurements, first in a model organism (ex. M. smegmatis)
and ultimately in M. tuberculosis. Such structure-based drug design
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efforts are enabled by the results we have presented here, and are
currently underway.

Figure 7

(a) Result of docking into one of the intermediates in the thioredoxin

catalytic cycle, to demonstrate the presence of potential binding pockets at the
Trx/TrxR interface of sufficient size to accommodate potential inhibitors or drug leads.
After docking 10,000 compounds, the best scoring (lowest energy) docked structure
(shown in green, compound number CSDDD_6702) occupied a site at the interface of
TrxR (red) and TrxC (blue) in Panels A and B, with energy = −10 kcal/mol using
AutoDock4. (b) Expansion that shows the docking pose for CSDDD_6702. (c)
Expansion showing the crosspeak perturbations in a section of the 15N-1H HSQC upon
addition of 200 μM of compound CSDDD_6702 (blue) to a sample containing 200 μM
TrxC, 250 μM TrxR, and 0.80 mM NADPH (black). Interface residue W33(HE1) is
represented by the crosspeak at 10.2 ppm, which has been shifted upon binding
CSDDD-6702.
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In summary, we have determined high-resolution solution
structures for both redox states of thioredoxin C (TrxC) from M.
tuberculosis using NMR (backbone RMSD of 0.54 and 0.50 Å for TrxCox
and TrxCred, respectively). The secondary structure and folding of the
oxidized and reduced states of TrxC are nearly identical, with only
subtle changes around the active site cysteines, and with some
changes in loop regions. In the presence of the TrxR from M.
tuberculosis, it appears that TrxC binds to TrxR only when TrxR has a
reduced disulfide and cofactor (NADP(H)) bound. This was
demonstrated by the disappearance of cross peaks for residues in the
active site of TrxC, due to exchange broadening. The lack of other
chemical shift changes (or peak shape changes) suggests that there
are no significant structural changes to TrxC upon binding to TrxR.
Using our structures and chemical shift perturbation data, along with
the previously reported TrxR structure and structures for the
thioredoxin system from E. coli,40 we constructed structural models for
all the steps of the catalytic cycle of the M. tuberculosis thioredoxin
system (Fig. 3). These structures, significantly different from the
human thioredoxin system, should facilitate future mechanistic studies
of the M. tuberculosis thioredoxin system, and aid in the design of
inhibitors as potential drug leads. Indeed, initial analysis of these
structures have identified at least one potential binding pocket, which
is distinct from both substrate pockets, that could be pursued in
structure-based drug design efforts. Inhibitors of the M. tuberculosis
thioredoxin system may serve as chemical probes to study this
pathogen’s ability to survive intracellular redox stress, in addition to
providing a new class of anti-mycobacterial agents.

Supplementary Material
Supp FigureS1-S6
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Figure S1.

Overlays of both redox states of solution structures from E. coli Trx

and M. tuberculosis TrxC, where A) is the overlay for the oxidized states, with blue
being from M. tuberculosis and green from E. coli and B) is the overlay for the reduced
states, with wheat being from M. tb and purple from E. coli.
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Figure S2.

2D 1H-15N HSQC spectra where the black cross peaks in all panels are

for oxidized/reduced TrxC and A) TrxR has been added to the sample (red), B) TrxR
has been added to the sample and the redox activity initiated by addition of with
NADPH to reduce TrxC (green), and C) DTT is added to the sample to fully reduce TrxC
as a control experiment (blue). Protein concentration is 250 μM for TrxC and TrxR is
slightly less than 250 μM.
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Figure S2 continued.

2D 1H-15N HSQC spectra where D) black cross peaks

are for oxidized/reduced TrxC and TrxR is added to the sample along with the oxidized
cofactor NADP+. E) The overlay of the DTT reduced sample (blue) and the NADPH
reduced sample (green), and F) is the same as panel E with the oxidized sample from
panel D and DTT added to it (orange).
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Figure S3.

Top panel: Calculated order parameters, based on the Random Coil

Index (RCI), from the Wishart group. Bottom panel: structure of TrxC (reduced)
showing those segments (in red) with the greatest disorder, predicted to be random
coil. The

α1 and α4 helices are shown on the left and right sides, respectively, in the

above representation.
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Figure S4.

Structure of TrxC showing location of last contiguously assigned

residue, Asn116. The C-terminal histidine tag was present after Asn116 (some
residues in the histidine tag were assigned as well).
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Figure S5.

Absorbance spectrum of a TrxR sample (28 μM) at 25 degrees in a 50

mM phosphate buffer at pH 7.6, obtained using an HP 8452 diode array UV-Vis
spectrophotometer. Relative band intensity and shape matches that which was
previously reported for the E. coli thioredoxins (Prongay, A.J., Engelke, D.R., and
Williams, C.H., Jr. (1989) J. Biol. Chem. 264, 2656-2664).

Figure S6. Physical model of the TrxR/TrxC structural that was built with students
from Messmer High School (Giovanni Rodriguez, Kevonna Nathaniel, Anwuri Osademe
and David Gonzalez), and their teacher Carol Johnson, to introduce students to
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structural biology research. This then led to production of a molecular animation of the
TrxR/TrxC catalytic cycle in partnership with Milwaukee School of Engineering, as a
teaching tool (under the NSF-funded CReST program).
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DMSO dimethylsulfoxide
DTT

dithiothreitol

HSQC heronuclear single quantum coherence spectroscopy
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LB

Luria Bertani

MD

molecular dynamics

NOESY nuclear Overhauser effect spectroscopy
RMSD root mean square deviation
Trx

Thioredoxin

TrxR

Thioredoxin reductase

TOCSY total correlation spectroscopy
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